Dicerna’s latest deal lands $200M, Roche as partner in HBV

A year after completing a pair of deals in the span of a week, Dicerna has partnered a Phase I HBV asset with Roche in an RNAi deal that brings in $200 million up front. The partnership continues the company’s string of partnerships in therapeutic areas outside of its scope, allowing it to

Read the full 533 word article

How to gain access

Continue reading with a
two-week free trial.